Douglas McNeel

33PUBLICATIONS
77CO-AUTHORS
Radiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jun 19, 2026
Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response.

|Apr 24, 2026
Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).

|Mar 04, 2026
Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.

David Jarrard, Jens Eickhoff, Christos E Kyriakopoulos

|Feb 27, 2026
Progression-Free Survival versus Overall Survival in Patients with PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP versus Placebo.

Douglas McNeel, Jens Eickhoff, Arianna Perez

|Dec 18, 2025
Toll like receptor agonist effects on human CD8+ T cell activation and expression of T cell checkpoint receptors.

Donghwan Jeon, Jena E Moseman, Ethan Hill

|Dec 11, 2025
Prostate tumor immune microenvironment changes following immunotherapy shared by patients who developed anti-tumor response or immune-related adverse events.

Ichwaku Rastogi, Douglas G McNeel

Pageof 6

Frequent Collaborators

6 joint publications

Jena E Moseman

4 joint publications

Ichwaku Rastogi

3 joint publications

Christos E Kyriakopoulos

2 joint publications

Melissa Gamat-Huber